The receptor tyrosine kinase (RET) inhibitors, selpercatinib and pralsetinib, were approved by the FDA for advanced or metastatic RETmutation-positive medullary thyroid cancer (MTC) or RET gene fusion-positive thyroid cancer. The gene discussed is RET; the disease is thyroid cancer.